The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.

about

The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q47109861

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@en

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@nl

type

Item

label

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@en

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@nl

prefLabel

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@en

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease.

@nl

P1476

The Innate and Adaptive Immune ...... in Inflammatory Bowel Disease

@en

P2093

Antonio Gasbarrini

http://www.w3.org/2001/XMLSchema#string

Cristina Graziani

http://www.w3.org/2001/XMLSchema#string

Franco Scaldaferri

http://www.w3.org/2001/XMLSchema#string

Gianluca Ianiro

http://www.w3.org/2001/XMLSchema#string

Grainne Holleran

http://www.w3.org/2001/XMLSchema#string

Loris Lopetuso

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Probiotics for induction of remission in Crohn's disease

Probiotics for induction of remission in ulcerative colitis

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22

Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Advances in the development of new biologics in inflammatory bowel disease

The epidemiology and risk factors of inflammatory bowel disease

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.

P31

scholarly article

P356

10.3390/IJMS18102020

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Deirdre McNamara

Valentina Petito

P5008

ScienceSource

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28934123

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

5666702

http://www.w3.org/2001/XMLSchema#string